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Schistosomiasis, caused by three principal species of diecious trematodes (flatworms),
currently afflicts over 250 million individuals, results in an estimated 2–15% chronic
disability, and contributes to poor health and economic stagnation in endemic areas.
Although schistosomiasis is effectively treated with praziquantel, rapid reinfection with
rebound morbidity precludes effective control based on chemotherapy alone and justifies
current efforts to develop vaccines for these parasites. Paramyosin (Pmy), an invertebrate
muscle-associated protein, has emerged as a promising vaccine candidate for both
Schistosoma mansoni and Schistosoma japonicum. Herein, we discuss the discovery of
Pmy, its development as a vaccine candidate in rodents and bovines, as well as studies
of naturally occurring immune responses to Pmy in prospective, observational human
studies. We conclude with a proposed developmental plan to move Pmy toward Phase I
clinical trials.
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Schistosomiasis, caused by three principle species of diecious trematodes (flatworms), currently
afflicts over 250 million people worldwide (1, 2) and results in 1.53 million DALYs lost per
annum (3), although this is likely a considerable underestimate. A recent reassessment of the
global burden of schistosomiasis suggests that the actual health burden is 4–30 times greater than
the previous WHO estimate (1, 4). Infection is characterized by the presence of adult worms
within the portal and mesenteric veins for Schistosoma japonicum and Schistosoma mansoni or
within the veins draining the urinary bladder for S. haematobium. Chronic infection results
in reduced childhood growth and nutritional status, anemia, hepatosplenomegaly, hepatic or
urinary bladder fibrosis, and bleeding esophageal varices. End organ and systemic pathology
result from granulomatous inflammation and fibrosis induced by parasite eggs trapped in host
tissues.
Efforts to mitigate the impact of schistosomiasis in endemic regions have focused on chemother-
apy of active infections with praziquantel (PZQ), control of intermediate snail hosts, and improved
sanitation.
In longitudinal cohort studies in the Philippines, we have demonstrated that improvements
in nutritional status and hemoglobin levels associated with PZQ treatment are transitory; both
nutritional status and hemoglobin returned to their pre-treatmentmorbid levels within 9–12months
(5). In addition, “rebound” morbidity, in which repeated cycles of annual treatment and rein-
fection result in more aggressive morbidity, has been described (6). Therefore, annual treatment
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3471
Jiz et al. Paramyosin
programs with PZQ are insufficient to reverse these morbidities,
while resource requirements to shorten the treatment interval
are prohibitive. Because current control strategies employing
chemotherapy with PZQ have not reduced transmission and
morbidity to acceptable levels, there is an urgent need for com-
plementary approaches, such as vaccines for schistosomiasis
control.
Discovery of Paramyosin
In S. mansoni, Sher and colleagues demonstrated that mice
vaccinated intradermally with schistosomula or adult worm
extracts adjuvanted with BCG were protected from cercarial chal-
lenge (7). The sera from these mice were strikingly monospe-
cific, recognizing a 97 kDa antigen in adult worm extracts and
immunoprecipitating a 97 kDa antigen from detergent extracts
of metabolically labeled worms (8). Size-fractionation analysis
of adult worm extracts indicated that only fractions containing
a protease sensitive 97 kDa antigen induced protection in this
model (7). Monoclonal antibodies against Sm97 were developed
from mice vaccinated intradermally with adult worm extract
and BCG (8). Indirect immunofluorescence using monoclonal
anti-Sm97 localized the antigen to regions just below the tegu-
ment and in the gut syncitia of adult worms. Sm97 was weakly
recognized by chronically infected mouse sera and not rec-
ognized by sera from mice infected with irradiated cercariae
(8). Immunoaffinity purified Sm97 was shown to elicit delayed-
type hypersensitivity in intradermally vaccinated mice, suggest-
ing that this molecule is also capable of evoking cell-mediated
responses.
A rabbit anti-Sm97 serum immunoprecipitated a 97 kDa anti-
gen from in vitro translation products of adult worm mRNA and
identified a 1317 base pair clone, which encoded approximately
50% of the native protein (9). The clone had 36% homology
with nematode myosin, but was designated paramyosin based
on amino acid composition and cross reactivity of anti-Sm97
sera with other native paramyosins. Structural analysis of the
deduced amino acid sequence and electron microscopy of puri-
fied schistosome paramyosin indicated that the protein adopts
an alpha helical coiled-coil conformation with a seven residue
repeat (10).
Paramyosin was localized to the contents of membrane bound
elongate bodies within the tegument and subtegumental cell bod-
ies using immunoelectron gold microscopy and polyclonal anti-
paramyosin antisera (11). Paramyosin was in a non-filamentous
form within these elongate bodies and staining was rarely
observed in the thick filaments of cortical muscle.
A full length cDNA clone of S. mansoni paramyosin was
sequenced and revealed significant homology to antigen B of
Taenia solium and the IgG Fc γ-binding protein of Taenia cras-
siceps (12, 13). These homologous proteins bind the Fc region
of IgG and collagen, and inhibit complement activation. Based
on these homologies, schistosome paramyosin was shown to
inhibit complement C1 and C9, and to bind polymeric collagen,
and IgG (14–17). These immune-related properties may explain
the tegumental localization of an otherwise muscle associated
protein.
Murine Protection Studies in S. mansoni
Passive transfer of monoclonal or polyclonal anti-paramyosin
antibodies did not protect mice from cercarial challenge (18);
however, immunization with 4µg of native or 40µg of a partial
recombinant paramyosin fragment with BCG induced 39 and
26% protection, respectively. These data suggested that protec-
tion induced by paramyosin was cell mediated and not antibody
dependent. Schistosome myosin and heterologous nematode
paramyosin did not induce protection, suggesting the requirement
of schistosome paramyosin specific epitopes for protection. In
other experiments, 5µg of native paramyosin induced 24–53%
protection in mice without adjuvant (19).
Native and partial recombinant paramyosin stimulated IFN-
γ production and macrophage killing of schistosomula in vacci-
nated mice. In addition, splenocytes from mice vaccinated with
paramyosin/BCG were stimulated to produce IFN-γ by 3-h-old
and 7-day-old schistosomula in a dose dependent fashion (18).
Pmy Development in S. japonicum
In contradistinction to the S. mansoni model, a mouse mon-
oclonal IgE antibody, subsequently demonstrated to recognize
paramyosin (20), was shown to confer 19–58% protection against
S. japonicum cercarial challenge following passive transfer (21,
22). In addition, the monoclonal stimulated eosinophill-mediated
killing of schistosomula in vitro (22).
To determine if paramyosin would also induce protection
against S. japonicum, we biochemically purified paramyosin
from S. japonicum adult worms. SDS-PAGE demonstrated a
single protein with a molecular weight of 97 kDa. In four
separate experiments, vaccination of mice with S. japonicum
paramyosin without adjuvant induced significant resistance
(62–86%, p< 0.001) against cercarial challenge as compared to
controls. These data suggest that S. japonicum paramyosin rep-
resents a promising candidate vaccine (23). Paramyosin has also
been evaluated as a component of a multi-antigen DNA-based
vaccine in mice; however, delivery in this format has not aug-
mented the level of protection seenwith recombinant or biochem-
ically purified native paramyosin (24).
Based on these encouraging protection data, McManus and
colleagues cloned the full length paramyosin gene from an S.
japonicum cDNA library probed with a hyperimmune rabbit sera
(25), whileNara et al. independently isolated the full-length cDNA
of Sj97 by screening a distinct library using a mouse monoclonal
IgE antibody, which recognizes a 97 kDa surface molecule on S.
japonicum larvae (26). Alignment of the predicted amino acid
sequences of S. mansoni and S. japonicum paramyosins revealed
95% identity.
Sj97 is the Target of Protective Th2 Biased
Cytokine Responses in Humans
We conducted a longitudinal treatment–reinfection study design
with 616 S. japonicum infected participants, 7–30 years of age. We
evaluated the relationship between cytokine responses made by
PMBCs in response to S. japonicum soluble adult worm extract
(SWAP), Sj97, Sj67, and Sj22.6, measured 4weeks after treatment
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with PZQ, and resistance to reinfection in a population from
Leyte, The Philippines. Reinfection was measured every 3months
for a total of 18months by duplicate Kato–Katz assessment on
three stools per person per timepoint. We employed repeated
measures models adjusted for both repeated measures within
person, clustering by household and several potential confounders
of reinfection intensity including: directly observed water contact,
socio-economic status, age, sex, village, and baseline intensity of
infection.
Schistosoma japonicum transmission was high: 54.8 and 91.1%
were reinfected within 6 and 18months, respectively. A Th2
bias in the following cytokine ratios, IL-5/IL-12, IL-13/IL-12,
FIGURE 1 | (A) Intensity of reinfection with S. japonicum 18months after
treatment with PZQ, as predicted by cytokine ratios in responses to SWAP
(N= 493). White and black bars represent the back-transformed LS mean
intensity of reinfection for the upper and lower quintile of IL13/IL12 log
cytokine-ratio distribution. Error bars represent SEs. LS mean estimates, SEs,
and p-values for difference in means between quintiles are adjusted for
confounders and clustering. Adapted from Ref. (26). (B) IgE responses to
rSj97 (paramyosin) predict resistance to S. japonicum reinfection at 12months
post-treatment, and are attenuated by lgG4. Least square (LS) means
represent the mean reinfection egg burden after adjusting for potential
confounders and clustering by household in a repeated measures model
using the combined Sj97 IgE and lgG4 response variable (p= 0.023 for time
by combined lgE–lgG4 variable interaction). Confounders in this model include
age, gender, village of residence, exposure, and baseline intensity. p-values
are for detailed comparisons between “lgG4 only” and the rest of the groups.
Error bars represent SEs. Reprinted from Ref. (27).
IL-4/IFN-g, IL-5/IFN-γ, and IL-13/IFN-γ, in response to Sj97,
predicted a 30–41% lower intensity of reinfection (all p< 0.05)
after adjustment for potential confounders. An example of one of
these protective relationships (for IL-13/IFN-γ ratio) is presented
in Figure 1A (27). Similar results were found for responses to
SWAP.
Sj97 is the Target of Protective IgE
Responses in Humans
Using the same study population and analytic approach described
for the cytokine analyses, we have evaluated the relationship
between antibodies to rSj97 and resistance to reinfection in
humans. We obtained serum 4weeks post-treatment and mea-
sured anti-rSj97 IgE, IgA, and IgG subclass specific antibody levels
using a bead-based assay. Responders were defined based on the
mean +2 SD of the fluorescence values obtained in a group of
10 unexposed North American controls. In repeated measures
models, individuals with IgE but not IgG4 responses to rSj97 had
a 77% lower intensity of reinfection at 12months compared to
individuals with IgG4 but not IgE responses, even after adjusting
for potential confounders including directly observed water con-
tact, village, age, sex, and baseline intensity of infection (p= 0.016)
(28), see Figure 1B.
Bovine Vaccine Trials
Using partially purified rSj97, McManus et al. (29) demonstrated
that Chinese buffalo immunized with rSj97 in Quill A devel-
oped specific anti-Sj97 antibodies and had 34% fewer worms
after laboratory challenge compared to controls. Importantly, the
authors also acknowledged that, “whereas the yields of rec-Sj97 are
sufficient for small trials, the expression levels are very low and are
inadequate for large-scale use.”
FIGURE 2 | Chromatographic purification of S. japonicum paramyosin.
A pET-30 plasmid containing paramyosin was expressed and purified similarly
as described (28). Lane 1, inclusion body preparation; lane 2, anion exchange
chromatography; lane 3, size exclusion chromatography; lane 4, purified S.
japonicum paramyosin with a thioredoxin fusion tag. Reprinted from Ref. (30).
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Pilot Scale Expression, Purification, and
Lyophilization of rSj97
As indicated above, recombinant Sj97 has not been successfully
produced at pilot scale despite considerable efforts (29, 30). After
discovering that Th2 and IgE responses to Sj97 were associated
with marked resistance to reinfection in humans, we have focused
our efforts on overcoming this scale-up challenge (31). Our typical
yield from a single 10 L fermentation is 600 lyophilized vials at
>0.250mg rSj97/vial.
Characterization of rSj97
We have conducted extensive functional, biochemical, biophys-
ical, and immunologic analyses on rSj97 to demonstrate that
our recombinant protein is free of concerning contaminants, is
correctly folded, and has appropriate functional properties. Elec-
trophoretic mobility and purity (Figure 2), sterility, endotoxin
level (by FDA approved test), residual SDS concentration, iden-
tity (LC-MS), secondary and tertiary structural analysis (CD),
collagen binding, IgG binding, and stability (>12months) gave
expected results (31).
Future Product Development for rSj97
Together with colleagues, we are actively pursuing vaccination
trials in bothmurine and bovinemodels with encouraging prelim-
inary results. These experiments are designed to evaluate several
doses of antigen as well as several adjuvants suitable for both
veterinary and human use. Because Schistosomiasis japonica is
a zoonosis, with bovines playing a key role in transmission to
humans (32, 33), we are also evaluating the impact of bovine
vaccination on human incidence of infection in endemic commu-
nities. Sj97 is a target of protective human IgE responses; therefore,
we are also evaluating the potential for inducing hypersensitivity
reactions by skin testing with rSj97 in infected bovines, again with
encouraging preliminary results. If successful, these data, together
with our GMP ready process for expression and purification, will
form a compelling argument to move recombinant paramyosins
toward Phase I trials in humans.
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